LZTS2 and hepatocellular carcinoma: Moreover, treatment with the 26S proteasome inhibitor MG132 led to increased LZTS2 protein levels in HCC cells, implying that LZTS2 is a liable protein that can be degraded by the UPS (Fig. 5d).